Based on the Galenica AG stock forecast from 0 analysts, the average analyst target price for Galenica AG is not available over the next 12 months. Galenica AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Galenica AG is Slightly Bearish, which is based on 7 positive signals and 9 negative signals. At the last closing, Galenica AG’s stock price was USD 75.25. Galenica AG’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
No recent analyst target price found for Galenica AG
No recent average analyst rating found for Galenica AG
Company Overview Galenica AG
Galenica AG operates as a healthcare service provider in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands. This segment also offers medication for treatment of patients at home; launches and distributes a portfolio of consumer health, pharmaceutical, and parapharmaceutical products; and marketing and sale services to partners in the healthcare market. The Logistics & IT segment provides range of specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers master data system for the healthcare market; develops management solutions for the healthcare market; group internal IT services; and publishes printed and electronic technical information on pharmaceutical products, as well as complete management solutions for pharmacies. The company was founded in 1927 and is headquartered in Bern, Switzerland. Read Less
Galenica AG operates as a healthcare service provider in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality ...Read More
Frequently Asked Questions About Galenica AG (GALNF) Stock
Stock Target Advisor's fundamental analysis for Galenica AG's stock is Slightly Bearish.
GALNF stock's dividend yield is 2.78%.
Our analysis grades GALNF stock's dividend yield at A+. This means that GALNF stock's dividend yield is above 100% of the stocks in the Medical Distribution sector in the OTC exchange.
Based on this GALNF may be a good dividend stock for its sector.
Unfortunately we do not have enough data on GALNF's stock to indicate what its average analyst target is.
GALNF stock's Price/Earning ratio is 20.23.
Our analysis grades GALNF stock's Price / Earning ratio at F. This means that GALNF stock's Price/Earning ratio is above 50% of the stocks in the Medical Distribution sector in the OTC exchange.
Based on this GALNF may be fairly valued for its sector
The last closing price of GALNF's stock was USD 75.25.
The most recent market capitalization for GALNF is USD 4.02B.
Unfortunately we do not have enough analyst data on GALNF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Galenica AG's stock.
As per our most recent records Galenica AG has 7,955 Employees.
Galenica AG's registered address is Untermattweg 8, Bern, Switzerland, 3027.
You can get more information about it from Galenica AG's website at https://www.galenica.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Galenica AG (GALNF) Stock
Stock Target Advisor's fundamental analysis for Galenica AG's stock is Slightly Bearish.
GALNF stock's dividend yield is 2.78%.
Our analysis grades GALNF stock's dividend yield at A+. This means that GALNF stock's dividend yield is above 100% of the stocks in the Medical Distribution sector in the OTC exchange.
Based on this GALNF may be a good dividend stock for its sector.
Unfortunately we do not have enough data on GALNF's stock to indicate what its average analyst target is.
GALNF stock's Price/Earning ratio is 20.23.
Our analysis grades GALNF stock's Price / Earning ratio at F. This means that GALNF stock's Price/Earning ratio is above 50% of the stocks in the Medical Distribution sector in the OTC exchange.
Based on this GALNF may be fairly valued for its sector
The last closing price of GALNF's stock was USD 75.25.
The most recent market capitalization for GALNF is USD 4.02B.
Unfortunately we do not have enough analyst data on GALNF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Galenica AG's stock.
As per our most recent records Galenica AG has 7,955 Employees.
Galenica AG's registered address is Untermattweg 8, Bern, Switzerland, 3027.
You can get more information about it from Galenica AG's website at https://www.galenica.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GALNF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
